Discovery of a novel dual EGFR/HER-2 inhibitor

被引：0
|
作者：
不详
机构：
来源：
PHARMACOGENOMICS | 2010年 / 11卷 / 06期
关键词：
RESISTANCE; GEFITINIB;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：745 / 745
页数：1
相关论文
共 50 条
  • [21] Discovery of 3,3a,4,5-tetrahydro-2H-benzo[g]indazole containing quinoxaline derivatives as novel EGFR/HER-2 dual inhibitors
    Zong, Xi
    Cai, Jin
    Chen, Junqing
    Sun, Chunlong
    Li, Lushen
    Ji, Min
    RSC ADVANCES, 2015, 5 (32): : 24814 - 24823
  • [22] Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
    Li, Xin
    Yang, Changyong
    Wan, Hong
    Zhang, Ge
    Feng, Jun
    Zhang, Lei
    Chen, Xiaoyan
    Zhong, Dafang
    Lou, Liguang
    Tao, Weikang
    Zhang, Lianshan
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 110 : 51 - 61
  • [23] EGFR activity in HER-2 over-expressing metastatic breast cancer:: Evidence for simultaneous phosphorylation of Her-2/neu and EGFR
    Gschwantler-Kaulich, D
    Hudelist, G
    Koestler, WJ
    Czerwenka, K
    Mueller, R
    Helmy, S
    Ruecklinger, E
    Kubista, E
    Singer, CF
    ONCOLOGY REPORTS, 2005, 14 (02) : 305 - 311
  • [24] BIBW-2992 Dual EGFR/HER2 Inhibitor Oncolytic
    Campas, C.
    Castaner, R.
    Bolos, J.
    DRUGS OF THE FUTURE, 2008, 33 (08) : 649 - 654
  • [25] A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
    Whang, Young E.
    Armstrong, Andrew J.
    Rathmell, W. Kimryn
    Godley, Paul A.
    Kim, William Y.
    Pruthi, Raj S.
    Wallen, Eric M.
    Crane, Jeffrey M.
    Moore, Dominic T.
    Grigson, Gayle
    Morris, Karla
    Watkins, Catharine P.
    George, Daniel J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (01) : 82 - 86
  • [26] Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
    Montemurro, Filippo
    Valabrega, Giorgio
    Aglietta, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) : 257 - 268
  • [27] Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    Konecny, G. E.
    Venkatesan, N.
    Yang, G.
    Dering, J.
    Ginther, C.
    Finn, R.
    Rahmeh, M.
    Fejzo, M. Schoenberg
    Toft, D.
    Jiang, S-W
    Slamon, D. J.
    Podratz, K. C.
    BRITISH JOURNAL OF CANCER, 2008, 98 (06) : 1076 - 1084
  • [28] Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    G E Konecny
    N Venkatesan
    G Yang
    J Dering
    C Ginther
    R Finn
    M Rahmeh
    M Schoenberg Fejzo
    D Toft
    S-W Jiang
    D J Slamon
    K C Podratz
    British Journal of Cancer, 2008, 98 : 1076 - 1084
  • [29] Synthesis and labeling of a novel EGFR and HER-2 tyrosine kinase inhibitor containing 4-anilinoquinoline-3-carbonitrile nucleus
    Theeraladanon, Chumpol
    Tateishi, Ukihide
    Shiina, Masaaki
    Minamimoto, Ryogo
    Endo, Hisashi
    Oka, Takashi
    Takahashi, Nobukazu
    Inoue, Tomio
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [30] 5-SubstitutedQuinazoline Derivatives as novel PET Imaging Probes of EGFR and HER-2
    Pimple, Surekha
    Ratib, Osman
    Scapozza, Leonardo
    Seimbille, Yann
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 : S219 - S219
12345